- Home
- LCTX vs ODYS Comparison
LCTX vs ODYS Comparison
Compare LCTX & ODYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- ODYS
- Stock Information
- Founded
- LCTX 1990
- ODYS N/A
- Country
- LCTX United States
- ODYS Israel
- Employees
- LCTX N/A
- ODYS N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- ODYS
- Sector
- LCTX Health Care
- ODYS
- Exchange
- LCTX Nasdaq
- ODYS NYSE
- Market Cap
- LCTX 95.2M
- ODYS 107.4M
- IPO Year
- LCTX N/A
- ODYS N/A
- Fundamental
- Price
- LCTX $0.49
- ODYS $5.55
- Analyst Decision
- LCTX Strong Buy
- ODYS Strong Buy
- Analyst Count
- LCTX 5
- ODYS 1
- Target Price
- LCTX $4.20
- ODYS $10.00
- AVG Volume (30 Days)
- LCTX 1.3M
- ODYS 29.5K
- Earning Date
- LCTX 05-08-2025
- ODYS 03-28-2025
- Dividend Yield
- LCTX N/A
- ODYS N/A
- EPS Growth
- LCTX N/A
- ODYS N/A
- EPS
- LCTX N/A
- ODYS N/A
- Revenue
- LCTX $9,499,000.00
- ODYS $3,964,000.00
- Revenue This Year
- LCTX N/A
- ODYS N/A
- Revenue Next Year
- LCTX $232.66
- ODYS N/A
- P/E Ratio
- LCTX N/A
- ODYS N/A
- Revenue Growth
- LCTX 6.19
- ODYS 30.70
- 52 Week Low
- LCTX $0.37
- ODYS $5.12
- 52 Week High
- LCTX $1.40
- ODYS $10.80
- Technical
- Relative Strength Index (RSI)
- LCTX 54.53
- ODYS N/A
- Support Level
- LCTX $0.37
- ODYS N/A
- Resistance Level
- LCTX $0.44
- ODYS N/A
- Average True Range (ATR)
- LCTX 0.04
- ODYS 0.00
- MACD
- LCTX 0.01
- ODYS 0.00
- Stochastic Oscillator
- LCTX 81.99
- ODYS 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.